Please login to the form below

Not currently logged in
Email:
Password:

upadacitinib

This page shows the latest upadacitinib news and features for those working in and with pharma, biotech and healthcare.

Incyte’s JAK inhibitor cream clears second eczema trial

Incyte’s JAK inhibitor cream clears second eczema trial

The latter group includes Pfizer’s Xeljanz, (tofacitinib), Eli Lilly’s Olumiant (baricitinib) and AbbVie’s Rinvoq (upadacitinib), which have been approved for rheumatoid arthritis but are also in testing for

Latest news

More from news
Approximately 2 fully matching, plus 32 partially matching documents found.

Latest Intelligence

  • 20 for 2020 – Five pharma companies to watch 20 for 2020 – Five pharma companies to watch

    AbbVie needs its new products to deliver quickly, and that includes recently approved JAK inhibitor Rinvoq (upadacitinib) for arthritis and psoriasis therapy Skyrizi (risankizumab) – both tipped as possible future blockbusters despite

  • Orphan drugs and breakthrough therapies drive Cortellis Drugs to Watch 2019 Orphan drugs and breakthrough therapies drive Cortellis Drugs to Watch 2019

    Upadacitinib, from AbbVie, treats rheumatoid arthritis. Upadacitinib is an orally dosed inhibitor of an intracellular target called JAK1. ... Upadacitinib was filed for approval in the US and EU in December 2018 and accepted for US Priority Review in

  • Drug launches to watch in 2019 Drug launches to watch in 2019

    It announced the filing of upadacitinib in the US and Europe on 20 December, with the filing of risankizumab expected early this year. ... Likewise, upadacitinib will face competition in both RA and atopic dermatitis, particularly from filgotinib.

More from intelligence
Approximately 0 fully matching, plus 3 partially matching documents found.

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Oxford University Press

Oxford University Press publishes over 100 prestigious, highly cited, and authoritative medical journals, many in collaboration with some of the...

Latest intelligence

Guide
How to embrace behavioural science principles in healthcare MR...
Top 10 ways to leverage the Impetus InSite Platform® to (virtually) launch your brand
The Impetus InSite Platform® can be used to facilitate virtual and hybrid engagement at all stages of the product lifecycle. Here, we share 10 of the most popular ways to...
Employee wellbeing in creative agencies: three tips to get you started
Paul Hutchings, founder of fox&cat, and new friend, Welfy, a workplace wellbeing training firm, discuss the importance of collaboration...